All Stories

  1. Berberine-Loaded Liposomes for the Treatment of Leishmania infantum-Infected BALB/c Mice
  2. Protective Passive Immunity in Escherichia coli ETEC-Challenged Neonatal Mice Conferred by Orally Immunized Dams with Nanoparticles Containing Homologous Outer Membrane Vesicles
  3. Zein-based nanoparticles for the oral delivery of insulin
  4. Zein nanoparticles improve the oral bioavailability of resveratrol in humans
  5. Protein-based nanoparticles for drug delivery purposes
  6. Intranasal delivery system of bacterial antigen using thermosensitive hydrogels based on a Pluronic-Gantrez conjugate
  7. Preparación, radiomarcaje con 99mTc y 67Ga y estudios de biodistribución de nanopartículas de albúmina con recubrimientos poliméricos
  8. In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer
  9. Encapsulation of probiotics in soybean protein-based microparticles preserves viable cell concentration in foods all along the production and storage processes
  10. Oral Immunogenicity in Mice and Sows of Enterotoxigenic Escherichia Coli Outer-Membrane Vesicles Incorporated into Zein-Based Nanoparticles
  11. Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate
  12. Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions
  13. Dissolving Microneedles for Intradermal Vaccination against Shigellosis
  14. Casein nanoparticles in combination with 2-hydroxypropyl-β-cyclodextrin improves the oral bioavailability of quercetin
  15. Nanoparticles from Gantrez® AN-poly(ethylene glycol) conjugates as carriers for oral delivery of docetaxel
  16. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization
  17. Mannosylated Nanoparticles for Oral Immunotherapy in a Murine Model of Peanut Allergy
  18. In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)
  19. The effect of thiamine-coating nanoparticles on their biodistribution and fate following oral administration
  20. Understanding the basis of transcutaneous vaccine delivery
  21. Towards a subunit vaccine from a Shigella flexneri ΔtolR mutant
  22. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions
  23. Increased Oral Bioavailability of Resveratrol by Its Encapsulation in Casein Nanoparticles
  24. Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using C. elegans
  25. Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel
  26. Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice
  27. Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy
  28. Human serum albumin nanoparticles for ocular delivery of bevacizumab
  29. Coencapsulation of cyclodextrins into poly(anhydride) nanoparticles to improve the oral administration of glibenclamide. A screening on C. elegans
  30. Evaluation of the treatment with resveratrol-loaded nanoparticles in intestinal injury model caused by ischemia and reperfusion
  31. Poly(anhydride) nanoparticles containing cashew nut proteins can induce a strong Th1 and Treg immune response after oral administration
  32. Soybean protein-based microparticles for oral delivery of probiotics with improved stability during storage and gut resistance
  33. Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections
  34. Special Issue: Pharmaceutics and Drug Delivery in Spain
  35. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles
  36. Optimization and evaluation of zein nanoparticles to improve the oral delivery of glibenclamide. In vivo study using C. elegans
  37. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis
  38. Corrigendum to ‘Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery’ [International Journal of Pharmaceutics 517 (2017) 67-79]
  39. Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.
  40. Genotoxic evaluation of poly(anhydride) nanoparticles in the gastrointestinal tract of mice
  41. Supramolecular structure of glibenclamide and β-cyclodextrins complexes
  42. Adjuvants for allergy immunotherapeutics
  43. Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccine
  44. Toxicity and biodistribution of orally administered casein nanoparticles
  45. Zein nanoparticles as vehicles for oral delivery purposes
  46. In vitro evaluation of the genotoxicity of poly(anhydride) nanoparticles designed for oral drug delivery
  47. Nanoaggregation of inclusion complexes of glibenclamide with cyclodextrins
  48. Topical immunization using a nanoemulsion containing bacterial membrane antigens
  49. Improved effect of amikacin-loaded Poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles against Planktonic and biofilm cells of Pseudomonas aeruginosa
  50. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer’s disease
  51. Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery
  52. Zein nanoparticles for oral delivery of quercetin: Pharmacokinetic studies and preventive anti-inflammatory effects in a mouse model of endotoxemia
  53. New pharmaceutical approaches for the treatment of food allergies
  54. Amikacin loaded PLGA nanoparticles against Pseudomonas aeruginosa
  55. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells
  56. Synthesis of Electroneutralized Amphiphilic Copolymers with Peptide Dendrons for Intramuscular Gene Delivery
  57. Oral delivery of camptothecin using cyclodextrin/poly(anhydride) nanoparticles
  58. Zein nanoparticles for oral folic acid delivery
  59. Study of Thermal Degradation of PLGA, PLGA Nanospheres and PLGA/Maghemite Superparamagnetic Nanospheres
  60. Interactions of poly (anhydride) nanoparticles with macrophages in light of their vaccine adjuvant properties
  61. In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration
  62. Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice
  63. Toxicity evaluation of nanocarriers for the oral delivery of macromolecular drugs
  64. Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization
  65. Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles
  66. Abstract 4067: Pluronic micelle-encapsulated Disulfiram targets cancer stem-like cells and reverses pan-resistance in acquired resistant breast cancer cell lines
  67. Zein-Based Nanoparticles Improve the Oral Bioavailability of Resveratrol and Its Anti-inflammatory Effects in a Mouse Model of Endotoxic Shock
  68. Casein nanoparticles as carriers for the oral delivery of folic acid
  69. Co-Encapsulated CpG Oligodeoxynucleotides and Ovalbumin in PLGA Microparticles; An in vitro and in vivo Study
  70. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation
  71. Nanoparticles as Adjuvants for Vaccination
  72. Development of a Bacterial Nanoparticle Vaccine
  73. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo
  74. Nanoparticle based-immunotherapy against allergy
  75. Pharmacokinetics and antitumor efficacy of paclitaxel–cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration
  76. Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles
  77. Influence of Cyclodextrin Derivatives on In Vitro Release of Cyclosporine A from Poly(anhydride) Nanoparticles
  78. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis
  79. Vaccine Delivery Systems for Veterinary Immunization
  80. Thermosensitive hydrogels of poly(methyl vinyl ether-co-maleic anhydride) – Pluronic® F127 copolymers for controlled protein release
  81. Superparamagnetic maghemite loaded poly (?- caprolactone) nanocapsules : characterization and synthesis optimization
  82. PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania
  83. Antigen Delivery Systems as Oral Adjuvants
  84. Cytotoxicity and Cell Interaction Studies of Bioadhesive Poly(anhydride) Nanoparticles for Oral Antigen/Drug Delivery
  85. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice
  86. Optimization of maghemite-loaded PLGA nanospheres for biomedical applications
  87. Towards a non-living vaccine against Shigella flexneri: From the inactivation procedure to protection studies
  88. Nanoparticules mucopénétrantes : véhicules pour l’administration orale du paclitaxel
  89. Radiomarcaje y estudios de biodistribución de nanopartículas poliméricas como adyuvantes para la vacunación oftálmica frente a la brucelosis
  90. Poly(ethylene oxide)-block-poly(n-butyl acrylate)-block-poly(acrylic acid) triblock terpolymers with highly asymmetric hydrophilic blocks: synthesis and aqueous solution properties
  91. Recent progress towards development of aShigellavaccine
  92. Development of poly(anhydride) nanoparticles loaded with peanut proteins: The influence of preparation method on the immunogenic properties
  93. Stabilized micelles as delivery vehicles for paclitaxel
  94. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles
  95. Innovative Lead Compounds and Formulation Strategies As Newer Kinetoplastid Therapies
  96. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study
  97. Low efficacy of NcGRA7, NcSAG4, NcBSR4 and NcSRS9 formulated in poly-ɛ-caprolactone against Neospora caninum infection in mice
  98. Toxicity Studies of Poly(Anhydride) Nanoparticles as Carriers for Oral Drug Delivery
  99. Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas
  100. Chapter 2.3. Nanostructures for Oral Vaccine Delivery
  101. Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease
  102. Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy
  103. Molecular buckets: cyclodextrins for oral cancer therapy
  104. Gantrez AN Nanoparticles for Ocular Delivery of Memantine: In vitro Release Evaluation in Albino Rabbits
  105. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice
  106. Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators
  107. Nanomedicine: Novel approaches in human and veterinary therapeutics
  108. Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone
  109. Bioadhesive properties of poly(anhydride) nanoparticles coated with different molecular weights chitosan
  110. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery
  111. Nanoparticles for the Oral Administration of Cancer Therapies
  112. Molecular Imaging Techniques to Study the Biodistribution of Orally Administered 99mTc-Labelled Naive and Ligand-Tagged Nanoparticles
  113. Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation
  114. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles
  115. Toxicity studies of poly(anhydride) nanoparticles
  116. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles
  117. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams
  118. Influence of the chitosan nature on the transfection efficacy of DNA-loaded nanoparticles after hydrodynamic administration in mice
  119. Different approaches for determination of the attachment degree of polyethylene glycols to poly(anhydride) nanoparticles
  120. Poly anhydride nanoparticles as adjuvants for mucosal vaccination
  121. Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel
  122. New adjuvants: from empiricism to science
  123. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne
  124. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination
  125. Design and influence of γ-irradiation on the biopharmaceutical properties of nanoparticles containing an antigenic complex from Brucella ovis
  126. Bioadhesive properties and biodistribution of cyclodextrin–poly(anhydride) nanoparticles
  127. Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria
  128. Co-Delivery of Ovalbumin and CpG Motifs into Microparticles Protected Sensitized Mice from Anaphylaxis
  129. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis
  130. Stability of Poly(ε-caprolactone) Microparticles Containing Brucella ovis Antigens as a Vaccine Delivery System Against Brucellosis
  131. New methodologies to characterize the effectiveness of the gene transfer mediated by DNA-chitosan nanoparticles
  132. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology
  133. Evaluation of Bioadhesive Capacity and Immunoadjuvant Properties of Vitamin B12-Gantrez Nanoparticles
  134. Mannose-targeted systems for the delivery of therapeutics
  135. Nanomedicina: nanopartículas con aplicaciones médicas
  136. Development of bioadhesive amino-pegylated poly(anhydride) nanoparticles designed for oral DNA delivery
  137. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles
  138. Albumin Nanoparticles
  139. Plant Protein-based Nanoparticles
  140. An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles
  141. Lyophilization of adenoviral vectors for gene therapy
  142. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens
  143. Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice
  144. Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles
  145. Nanoparticles as Adjuvant-Vectors for Vaccination
  146. Intradermal immunization with ovalbumin-loaded poly-?-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice
  147. Gamma Interferon Loaded onto Albumin Nanoparticles: In Vitro and In Vivo Activities against Brucella abortus
  148. Encapsulation of antigenic extracts of Salmonella enterica serovar
  149. Chemical and Biological Factors in the Control of Brucella and Brucellosis
  150. Bioadhesive Mannosylated Nanoparticles for Oral Drug Delivery
  151. Development of a Novel Vaccine Delivery System Based on Gantrez Nanoparticles
  152. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice
  153. Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams
  154. Optimization of the entrapment of bacterial cell envelope extracts into microparticles for vaccine delivery
  155. Simultaneous quantification of different cyclodextrins and Gantrez by HPLC with evaporative light scattering detection
  156. Salmonella-like bioadhesive nanoparticles
  157. Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice
  158. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties
  159. Bioadhesive properties of pegylated nanoparticles
  160. Albumin Nanoparticles for the Intravitreal Delivery of Anticytomegaloviral Drugs
  161. Potential of Albumin Nanoparticles as Carriers for Interferon Gamma
  162. Protective ability of subcellular extracts from Salmonella Enteritidis and from a rough isogenic mutant against salmonellosis in mice
  163. Bioadhesive Properties of Gantrez Nanoparticles
  164. Potential of Albumin Nanoparticles as Carriers for Interferon Gamma
  165. Humoral immune response in hens naturally infected withSalmonellaEnteritidis against outer membrane proteins and other surface structural antigens
  166. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes
  167. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines
  168. New Therapeutic Approaches for the Treatment of Brucella Infections: Gentamicin Entrapment into Drug Delivery Systems
  169. Influence of the co-encapsulation of different excipients on the properties of polyester microparticle-based vaccine against brucellosis
  170. In vivo sustained release of adenoviral vectors from poly(d,l-lactic-co-glycolic) acid microparticles prepared by TROMS
  171. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide
  172. Fluconazole encapsulation in PLGA microspheres by spray-drying
  173. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice
  174. Bovine Serum Albumin Modified the Intracellular Distribution and Improved the Antiviral Activity of an Oligonucleotide
  175. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties
  176. Corrigendum to: “Gantrez® AN as a new polymer for the preparation of ligand–nanoparticle conjugates”
  177. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): evaluation of its integrity and controlled release properties
  178. Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens
  179. Gantrez® AN as a new polymer for the preparation of ligand–nanoparticle conjugates
  180. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide
  181. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis
  182. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles
  183. RP–LC determination of 5-fluorouridine in nanoparticulate formulations
  184. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats
  185. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres
  186. Polyester Microparticles as a Vaccine Delivery System for Brucellosis: Influence of the Polymer on Release, Phagocytosis and Toxicity
  187. Efficacy of Ganciclovir-loaded Nanoparticles in Human Cytomegalovirus (HCMV)-infected Cells
  188. Adaptive Immune Responses of Legumin Nanoparticles
  189. In Vitro Antileishmanial Activity of Amphotericin B Loaded in Poly(ε-Caprolactone) Nanospheres
  190. A Brucella ovis antigenic complex bearing poly-ε-caprolactone microparticles confer protection against experimental brucellosis in mice
  191. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties
  192. Rapid determination of intramacrophagic amphotericin B by direct injection HPLC
  193. Bioadhesive potential of gliadin nanoparticulate systems
  194. In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188
  195. RESEARCH NOTE - Evaluation and Characterisation of Gliadin Nanoparticles and Isolates by Reversed-Phase HPLC
  196. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections
  197. Determination of oligonucleotide ISIS 2922 in nanoparticulate delivery systems by capillary zone electrophoresis
  198. Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography
  199. Biopolymer and polymer nanoparticles and their biomedical applications
  200. Distribution of Albumin Nanoparticles in Animals Induced with the Experimental Allergic Encephalomyelitis
  201. Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus
  202. Electrophoretic separation and characterisation of gliadin fractions from isolates and nanoparticulate drug delivery systems
  203. Gliadin nanoparticles: formation, all‐ trans‐retinoic acid entrapment and release, size optimization
  204. Gliadin nanoparticles: formation, all-trans-retinoic acid entrapment and release, size optimization
  205. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract
  206. Interaction of amphotericin B with polymeric colloids
  207. Interaction of amphotericin B with polymeric colloids: 2. Effect of poloxamer on the adsorption of amphotericin B onto poly(ϵ-caprolactone) nanospheres
  208. Development of Drug-delivery Systems from Vegetal Proteins: All-trans-retinoic Acid-loaded Gliadin Nanoparticles
  209. Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity
  210. Preparation of lectin-vicilin nanoparticle conjugates using the carbodiimide coupling technique
  211. Gliadin nanoparticles for the controlled release of all-trans-retinoic acid
  212. Development of Drug Delivery Systems from Vegetal Proteins: Legumin Nanoparticles
  213. Optimization and in vitro stability of legumin nanoparticles obtained by a coacervation method
  214. Mucin Interactions with Functionalized Polystyrene Latexes
  215. In vitro study of lectin-latex conjugates for specific bioadhesion
  216. Preparation and characterization of lectin-latex conjugates for specific bioadhesion
  217. Stability of some phenolic antioxidants in fatty preparations
  218. Determination of particle concentration in latexes by turbidimetry
  219. HPLC determination of antioxidant synergists and ascorbic acid in some fatty pharmaceuticals, cosmetics and food
  221. Study of the interactions between nanoparticles and intestinal mucosa